How does The Freedom Stack work? What is its mechanism of action?

Reported Mechanisms — Component by Component Each section below summarizes the published mechanism of a single component. No combined mechanism is described in the literature, and none is asserted here. 1. GLP3-R / Retatrutide (30 mg, 1 vial) — Triple Receptor Agonism Retatrutide is described as engaging the GIP, GLP-1, and glucagon receptors with a single peptide sequence — the feature that distinguishes it from dual GIP/GLP-1 agonism and from GLP-1-selective agonism.[1] Clinical pharmacology h

What are the research applications of The Freedom Stack?

Research Applications (Component-Level) The published work behind each vial in this kit falls into the following areas. Every study listed used a single component, not the stack. Incretin and glucagon receptor pharmacology — retatrutide is the triple-agonist reference compound used to separate the contribution of glucagon-receptor engagement from GIP/GLP-1 agonism.[1][2] Metabolic and hepatic research — phase 2 trials of the pharmaceutical formulation have been published in obesity and type 2 di

What does the research summary say about The Freedom Stack?

Research Summary (Component-Level) No peer-reviewed study has evaluated this five-vial stack as a unit. The table below lists representative findings for each component individually. Full per-component data and complete reference lists are on the dedicated GLP3-R, SS-31, and KLOW pages. ComponentRepresentative StudyReported ObservationRef GLP3-RCoskun et al. (2022) — discoveryCharacterized as a triple glucagon, GIP, and GLP-1 receptor agonist[1] GLP3-RUrva et al. (2022) — phase 1bMultiple-ascend

How should The Freedom Stack be stored?

Store each lyophilized vial at -20°C (long-term). Reconstituted: -80°C for extended storage, 2-8°C for short-term use. Keep KLOW away from chelators (EDTA, carnosine, Vitamin C). Reconstitute and store each vial separately.

What Is The Freedom Stack?

Resposta Rapida

Overview The Freedom Stack groups three research materials that are each characterized in a separate body of published work. It ships as five individual vials, and the three literatures behind them do not overlap. GLP3-R is retatrutide (LY3437943). Coskun et al. published its discovery-to-clinical-p...

22 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: julho de 2026

Overview

The Freedom Stack groups three research materials that are each characterized in a separate body of published work. It ships as five individual vials, and the three literatures behind them do not overlap.

GLP3-R is retatrutide (LY3437943). Coskun et al. published its discovery-to-clinical-proof-of-concept characterization as a triple glucagon, GIP, and GLP-1 receptor agonist, and Urva et al. reported the phase 1b multiple-ascending-dose study.[1][2] Phase 2 trials in obesity and in type 2 diabetes have been published in NEJM and The Lancet respectively.[3][4] It remains an investigational compound with no regulatory approval.

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide. Szeto described it as a first-in-class cardiolipin-protective compound, and Birk et al. reported that it re-energizes ischemic mitochondria by interacting with cardiolipin and by targeting the cytochrome c/cardiolipin complex.[5][6][7]

KLOW is itself a four-peptide blend — GHK-Cu, BPC-157, TB-500, and KPV — whose components are characterized in the tissue-repair and inflammation literatures: copper-dependent gene and matrix modulation, VEGFR2-associated angiogenic signalling, G-actin binding, and melanocortin-derived anti-inflammatory activity respectively.[12][15][17][19]

No peer-reviewed study has evaluated these materials together as a stack. Every citation on this page describes a single component studied on its own, and no published work characterizes interactions among incretin-receptor agonism, mitochondrial cardiolipin binding, and tissue-repair peptide signalling. Investigators should treat the kit as three separate research materials and consult the dedicated GLP3-R, SS-31, and KLOW entries for complete mechanism, applications, and reference lists.

Editorial Research Note

“Research Summary (Component-Level) No peer-reviewed study has evaluated this five-vial stack as a unit.”

Pure U.S. Peptides Research Standards TeamInternal editorial group summarising published peptide research for an audience of qualified independent investigators.

Referencias

Perguntas de Pesquisa Relacionadas

→ The Freedom Stack: Mechanism of Action → The Freedom Stack: Research Applications → The Freedom Stack: Safety Profile & Research Summary → The Freedom Stack: Chemical Properties → Storing The Freedom Stack: Best Practices

Browse all research guides in the Peptide Research Library →

Deseja a revisao completa da pesquisa?

Ver Pagina Completa de Pesquisa de The Freedom Stack→

APENAS PARA USO EM PESQUISA

Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.